Secukinumab in psoriasis: A single-center experience

Secukinumab in psoriasis: A single-center experience

Background and Design: Several randomized clinical trials demonstrated the safety and efficacy of secukinumab in the systemic treatment of moderate-severe psoriasis; however, real-life data is limited. Thus, this study aimed to assess the efficacy and safety of secukinumab in patients with psoriasis...

Full description

Bibliographic Details
Main Authors:	Esra Ağaoğlu, Hilal Kaya Erdoğan, Ersoy Acer, Zeynep Nurhan Saraçoğlu, Muzaffer Bilgin
Format:	Article
Language:	English
Published:	Galenos Publishing House 2021-09-01
Series:	Turkderm Turkish Archives of Dermatology and Venereology
Subjects:	secukinumab psoriasis biologic treatment efficacy safety
Online Access:	https://journal.turkderm.org.tr/jvi.aspx?pdir=turkderm&plng=eng&un=TURKDERM-75046&look4=

Similar Items

The significance of secukinumab in the treatment of plaque psoriasis
by: Marta Kasprowicz-Furmańczyk, et al.
Published: (2022-02-01)

Treatment challenges in the management of moderate-to-severe plaque psoriasis – role of secukinumab
by: Malakouti M, et al.
Published: (2016-10-01)

Secukinumab for the Treatment of Psoriasis in Pediatrics: Patient Selection and Acceptability
by: Narbutt J, et al.
Published: (2023-02-01)

Successful Treatment of Pediatric Generalized Pustular Psoriasis with Secukinumab
by: Yu K, et al.
Published: (2025-01-01)

Interleukin-17A Inhibitor Secukinumab Treatment in HIV-Positive Psoriasis Patient: A Case Report
by: Gong J, et al.
Published: (2022-12-01)

Secukinumab Therapy in Psoriasis Management
by: Ira Yunita, et al.
Published: (2022-03-01)

Complete treatment experience on psoriasis patients with secukinumab in real practice in Krasnodar region
by: L. S. Kruglova, et al.
Published: (2021-06-01)

Clinical efficacy and safety of secukinumab in the treatment of generalized pustular psoriasis in the pediatric population: a systematic review of the literature
by: Kebo Wei, et al.
Published: (2024-08-01)

Efficacy and safety of secukinumab for moderate to severe plaque psoriasis in children: A report of 10 cases
by: FU Tao, et al.
Published: (2024-10-01)

Secukinumab-induced paradoxical palmoplantar pustular psoriasis
by: Yıldız Gürsel Ürün, et al.
Published: (2022-12-01)

Risankizumab Versus Secukinumab: A Real-World Efficacy and Cost per Responder Comparison in Patients With Psoriasis in Italy
by: Federico Pirro, et al.
Published: (2025-01-01)

Secukinumab: In psoriasis and beyond
by: Aditya K. Bubna, et al.
Published: (2025-01-01)

Experience of using secukinumab in the treatmentof patients with psoriasis
by: N. V. Zilberberg, et al.
Published: (2021-11-01)

Clinical analysis of secukinumab in the treatment of childhood generalized pustular psoriasis
by: Min YU, et al.
Published: (2024-04-01)

Efficacy and safety of cyclosporin, adalimumab and secukinumab in the treatment of nail psoriasis
by: Zhanhan TANG, et al.
Published: (2023-04-01)

Paradoxical pustular psoriasis in a patient with spondyloarthritis treated with secukinumab
by: Daniela Anghel, et al.
Published: (2023-12-01)

Personalized Secukinumab Treatment in Patients with Plaque Psoriasis Using Model-Informed Precision Dosing
by: Karine Rodriguez-Fernandez, et al.
Published: (2024-12-01)

A case report of bullous pemphigoid following secukinumab therapy for a patient with psoriasis
by: Guanghan Wang, et al.
Published: (2024-12-01)

Long-Term Effectiveness and Drug Survival of Secukinumab in Vietnamese Patients with Psoriasis: Results from a Retrospective ENHANCE Study
by: Hao Trong Nguyen, et al.
Published: (2022-12-01)

Treatment of Erythrodermic Psoriasis in Children with Secukinumab: A Case Report
by: Lu X, et al.
Published: (2023-07-01)

Comparative Efficacy and Safety of Ustekinumab and Secukinumab in the Treatment of Generalized Pustular Psoriasis: A 48-Week Retrospective Cohort Study with Genetic Background Analysis
by: Ruan SF, et al.
Published: (2024-09-01)

Persistence of secukinumab in patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis
by: Elena Conesa-Nicolás, et al.
Published: (2021-01-01)

Identification immune response genes in psoriasis after treatment with secukinumab
by: Jing Wang, et al.
Published: (2023-04-01)

Secukinumab
by: Nilgün Atakan
Published: (2022-04-01)

Secukinumab in the Treatment of Psoriasis: A Narrative Review on Early Treatment and Real-World Evidence
by: Piergiorgio Malagoli, et al.
Published: (2024-09-01)

Response of Psoriasis with Systemic Lupus Erythematosus to Secukinumab: A Case Report and Review of the Literature
by: Dai B, et al.
Published: (2023-12-01)

Efficacy and Safety of Secukinumab in Elderly Patients with Moderate to Severe Plaque-Type Psoriasis: Post-Hoc Analysis of the SUPREME Study
by: Talamonti M, et al.
Published: (2023-04-01)

The real-life efficacy and safety of secukinumab therapy (150 and 300 mg) in patients with moderate-to-severe plaque psoriasis: A twelve week, single center, retrospective study
by: İncilay Kalay Yıldızhan, et al.
Published: (2021-09-01)

A Propensity Score-Matched Study on the Changes of TB Status and TB-IGRA Values in Patients with Psoriasis with Latent TB Receiving Secukinumab
by: Yue Xiao, et al.
Published: (2023-08-01)

Case report: Intralesional secukinumab injection for pediatric nail psoriasis: does it have to be a positive outcome?
by: Xuesong Wang, et al.
Published: (2024-10-01)

Prurigo Nodularis onset during secukinumab treatment of psoriasis: a case report
by: Qingqing Yang, et al.
Published: (2023-07-01)

Transition from secukinumab to adalimumab in COVID‐19‐induced psoriasis flare‐up treatment: A case report
by: Yuting Chen, et al.
Published: (2023-10-01)

Lack of reactivation of tuberculosis in patients with psoriasis treated with secukinumab in a real-world setting of latent tuberculosis infection
by: Matteo Megna, et al.
Published: (2022-07-01)

Clinical observation on the treatment of severe plaque psoriasis with liver dysfunction with secukinumab
by: Hui YE, et al.
Published: (2024-03-01)

Management of Moderate and Severe Forms of Psoriasis in Children: New Opportunities of Genetically Engineered Biologic Drugs
by: Leyla S. Namazova-Baranova, et al.
Published: (2021-11-01)

Successful Treatment of Refractory Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO) Syndrome and Paradoxical Psoriasis with Secukinumab: A Case Report
by: Fan D, et al.
Published: (2024-03-01)

Secukinumab: A safe option to treat psoriasis and psoriatic arthritis in the presence of interstitial lung disease
by: Raja Natarajan
Published: (2019-01-01)

Relapsing polychondritis associated with pustular psoriasis successfully treated with secukinumab: a case-based review
by: Qicheng Song, et al.
Published: (2024-07-01)

Anticytokine therapy with interleukin-17 in patients with moderate and severe psoriasis
by: Julia S. Kovaleva, et al.
Published: (2024-03-01)

A Real-Life 208 Week Single-Centred, Register-Based Retrospective Study Assessing Secukinumab Survival and Long-Term Efficacy and Safety Among Greek Patients With Moderate to Severe Plaque Psoriasis, Including Difficult-to-Treat Manifestations Such as Genitals and Scalp
by: Eirini Kyrmanidou, et al.
Published: (2024-04-01)